EndoChoice — Investor Presentation (November 2015)
38 slides from EndoChoice's investor presentation, Nov 5, 2015
Slide 1: A Platform GI Company
Mark Gilreath Founder & CEO David Gill Chief Financial Officer A Platform GI Company November 2015 Exhibit 99.1
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward‐looking statements. You should not rely upon forward‐looking statements as predictions of future events. All statements other than statements of historical facts contained in this presentation, including information concerning our possible or assumed fu
Slide 3: The Company
Q | The Company QENDCCHOICE
Slide 4: EndoChoice: A Platform Company Serving the GI Caregiver
EndoChoice: A Platform Company Serving the GI Caregiver
Slide 5: EndoChoice at a Glance
Platform GI Company Differentiated Tech $6B Market Proven Track Record + + Platform company focused across entire GI procedure cycle Fuse® detected 69% more pre-cancerous polyps, Cost effective technology $6B Global GI market, growing annually at 7% Management team with proven track record 2,500+ es
Slide 6: Management Strength
Management Strength Mark Gilreath Founder & CEO 23 years experience in GI market Former President, Americas Given Imaging, maker of PillCam technology Transformed Given Imaging from pre-revenue start-up to $120M NASDAQ-listed company David Gill Chief Financial Officer 20 years experience in medical
Slide 7: Scalable Infrastructure
>2,500 Customers in the US >Distributors in 30 countries 450 Employees Worldwide 285 100 65 Scalable Infrastructure Global Headquarters Alpharetta, GA USA West Coast Distribution Reno, NV USA Imaging Services Nashville, TN USA International Headquarters & Manufacturing Hamburg, Germany Research & De
Slide 8: GI Market Opportunity
e) Gl Market Opportunity QENDCCHOICE
Slide 9: EndoChoice Growth Drivers
Imaging Devices Pathology Infection Control Source: Markets & Markets, Endoscopy Equipment, Global Forecasts to 2018; The U.S. Anatomic Pathology Market, Forecast & Trends 2014-15; Annual Reports and EndoChoice Internal Estimates Note: Devices do not include ERCP and EUS opportunity EndoChoice Growt
Slide 10: Attractive Oncology End Markets
Attractive Oncology End Markets Gastric and esophageal cancer GERD monitoring Abdominal pain diagnosis National Colorectal Cancer Roundtable goal: Increase colorectal cancer screening rates from ~60% currently to 80% by 2018 Colorectal cancer screening – highly preventable if detected early ~1.4 mil
Slide 11: A World of Opportunity
Dilation Visualization Airway Personal Protection Inventory Mgt Diagnostic Tests Luminal Access Tissue Acquisition Patient Monitoring Luminal Patency Data Management EndoKits Preparation Suction Patient Service Hemostasis Cleaning Retrieval Transport Mobility Quality Measures Infection Risk A World
Slide 12: Fragmented GI Community
Fragmented GI Community Setup OME. MSKESSON “Keanna Scope Repair Equipment OLymPuS (we OLYMPUS PENTAX FUJIFILM GlyeN,, OeAreX ERBE Gl Clean & Disinfect Procedure Devices Ruwior CMetrex wears Cycle RET Rc aoa COVIDIEN Transport Pathology cD «smu LabCorp BACARS Poros Pre-Clean es RuHoFd cyexud) Ciletr
Slide 13: EndoChoice Platform
EndoChoice Platform Q Setup Cadi & Scope Repair Be Qe Clean & Disinfect Ztal WA Q Transport en © gon nd =a Pre-Clean Q Equipment i Q Devices AMA Q Pathology QENDCCHOICE Fy <a 2)
Slide 14: Proven Track Record in GI Innovation
Proven Track Record in GI Innovation ASP Range of $2 to $220,000
Slide 15: Three Growth Engines
Fuse® system Scope repair services and accessories Infection control products Therapeutic devices (forceps, snares, injection needles, retrieval) Advanced technology combined with highly trained GI pathologists Customized solutions to enhance care Total Imaging Single Use Products Pathology 2014 Rev
Slide 16: Fuse Full Spectrum Endoscopy
Fuse® Full Spectrum Endoscopy
Slide 17: Major Video Endoscopy Players
Major Video Endoscopy Players GI Flexible Endoscopy Surgical Endoscopy
Slide 18: A New Standard in GI Imaging
A New Standard in Gl Imaging QENDCCHOICE
Slide 19: Fuse Enabling Technologies
LEDs Fuse® Enabling Technologies Integrating LEDs and Multiple Imagers 3 Imagers Light Guides 1 Imager Traditional Colonoscope Fuse Colonoscope
Slide 20: Limited View with 170° Colonoscopy
Limited View with 170° Colonoscopy
Slide 21: 330° Field of View with Fuse
330° Field of View with Fuse® QUENDCCHOICE ———_ a O J = < te QENDCCHOICE 2
Slide 22: Compelling Clinical and Cost-Effectiveness Data
Compelling Clinical and Cost-Effectiveness Data Sources: Gralnek IM, Siersema PD, Rex DK, et al. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. The Lancet Oncology 2014; 15: 353-60. Hassan, et al, Cost-effecti
Slide 23: Speed of Innovation
Speed of Innovation 4K Single Monitor Locking Lever Brighter Image, Improved Quality StrataFlex Insertion Tube 2013 – Generation 1 2015 – Generation 2
Slide 24: Fuse Adds Value for All Stakeholders
Physician Significant GI advance Differentiated practice, more procedures Payor Cost saving technology Addressing problem of interval cancer Hospital/ASC Differentiated technology Marketing advantage Patient Reduced fear of missed polyps Increased confidence in negative exam Fuse® Adds Value for All
Slide 25: Driving Commercial Success
e) Driving Commercial Success QENDCCHOICE
Slide 26: Expanding Global Sales Presence
Global Headquarters Alpharetta, GA USA International Headquarters Hamburg, Germany 50 è 70 Direct sales territories in the US 30 International markets via distributors Expanding Global Sales Presence
Slide 27: US Expansion Combined with Optimization
US Expansion Combined with Optimization Expansion – Q4 2015 Imaging SUP Pathology 70 Territory Managers December 2014 December 2013 Since December 2013 (pre-Fuse), sales force is expanding from 50 reps to 90 total sales reps and 8 Regions to 11. With the new expansion, Territory Managers (TMs) sell
Slide 28: Established Reimbursement
Established Reimbursement Reimbursement Medicare Nat’l Avg Coding Description ASC Hospital G0121 Colonoscopy, Screening $569 $864 CPT 45385 Colonoscopy, with Polypectomy $747 $1,103 CPT 43235 EGD, (Gastroscopy) $545 $880 Pathology billed separately. Collections average $100 per specimen. Note: All f
Slide 29: Practice Marketing Tools
Practice Marketing Tools Colon ME Health Alert Bd | Spectrum Endoscopy Nt Fe rau 08 (Click Here WCamegie Hill | ASE QENDCCHOICE Ray = - ~<qi7 >=
Slide 30: Strong Financial Profile
Q Strong Financial Profile QENDCCHOICE
Slide 31: Consistent Revenue Growth Provides Foundation for Future
Consistent Revenue Growth Provides Foundation for Future First sales of Fuse® Generation 1 in late 2013 to gain experience; Started deliveries of Gen 2 in Q2 2015
Slide 32: Fuse Addresses $1 Billion Annual Opportunity
Fuse® Addresses $1 Billion Annual Opportunity ASPs U.S. – $205,000 ROW – $110,000 1,800 ASCs and 5,200 hospitals in the U.S. averaging 2+ systems each
Slide 33: 44% Average Quarterly Growth Fuse Sales
44% Average Quarterly Growth Fuse® Sales Installed base now exceeds 100 systems 81% of Fuse customers buy our Single Use Products
Slide 34: Two Growth Drivers for Single-Use Products
Two Growth Drivers for Single-Use Products: Customer count and Average Monthly Order (AMO) Presence in 2,500 GI departments (1/3 of U.S. market) will drive penetration 65% of our SUP customers buy multiple products SUP AMO for Fuse customers grew from $3,674 and $3,747 in Q3’15
Slide 35: Life Cycle Revenue Potential Per new ASC customer
Life Cycle Revenue Potential Per new ASC customer 2 Room ASC Revenue Value One Time Sale Fuse Video System, 2 Rooms $440,000 Recurring Revenue Devices $160,000 EndoKits $160,000 Endoscope Reprocessing $80,000 Endoscope Service $120,000 Pathology Billing $2,000,000 Total Recurring Revenue Over 5 Year
Slide 36: Path To Gross Margin Improvement
Path To Gross Margin Improvement – Gain Scale in Fuse Manufacturing Target Current State Fixed Manufacturing Overhead Units Produced Fixed OH per system Direct Materials per system Direct Labor per system Total Costs/System US ASP/System Gross Margin% $11.5M 100 $115 $75 $15 $205 $205 0% $15.0M 500
Slide 37: Path To Profitability
Path To Profitability Longer Term Operating Goals Gross margin expansion will be driven by: Spreading fixed manufacturing costs over higher unit volumes Design programs to reduce parts and improve manufacturability Greater purchasing leverage with vendors on higher volumes Long Term Goals Gross Marg
Slide 38: Strong Capitalization
Strong Capitalization (in millions) September 30, 2015 Actual Cash $102.7 Long-term debt $42.6 Net equity $110.1 Refinanced debt in June 2015 – lowering interest rate and deferring principal payments to January 2018 $15 Mil available under revolver
EndoChoice Holdings — Investor Presentation (November 2015) on 6ix